<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372888</url>
  </required_header>
  <id_info>
    <org_study_id>20.205.01e</org_study_id>
    <nct_id>NCT04372888</nct_id>
  </id_info>
  <brief_title>Examining Choice Architecture for Genetic Testing Decisions</brief_title>
  <official_title>Examining Choice Architecture for Genetic Testing Decisions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this application is to gain a deeper understanding of decision-making for genetic
      testing and identify effective choice-architecture-based strategies to improve decisions in
      genetic testing. The investigators hypothesize that choice architecture (i.e. framing)
      affects decision-making for hypothetical genetic testing scenarios.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing opt-in electronic consent, eligible consented participants will be randomized
      to one of two hypothetical genetic testing scenarios (rare, life-altering genetic condition
      or common, life-threatening genetic condition). The genetic testing scenarios include brief
      detailed information about genetic testing (i.e. how results may influence treatment
      decisions) as well as information about standard approaches to treatment. Subjects will be
      randomized to receive a framing conditions (e.g. choice, opt-in, opt-out, enhanced choice).
      Participants will select a preferred testing option to the hypothetical scenario and will
      complete several validated instruments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to 1 of 6 decision frames for two disease testing scenarios (arms)</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>participants are blinded to arm and decision frame</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic testing decision</measure>
    <time_frame>after reading the scenario and viewing frame (approximately 10 minutes)</time_frame>
    <description>Opting &quot;yes&quot; for genetic testing or &quot;no&quot; refusing genetic testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with Decision Scale (SWD)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>SWD is a validated 6-item instrument, items are scored on a 1-5 scale with higher scores indicating greater satisfaction with the decision taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decisional Regret Scale (DRS)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>DRS is a validated 5-item instrument, items are scored on a 1-5 scale with higher scores indicating more regret with the decision taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Newest Vital Sign (NVS)</measure>
    <time_frame>study completion (approximately 30 minutes)</time_frame>
    <description>NVS is a validated 6-item instrument, questions are based on reading and interpreting a food label, higher scores (more correct answers) indicate greater levels of literacy and numeracy abilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience with genetic disease</measure>
    <time_frame>Baseline (study onset)</time_frame>
    <description>Single &quot;yes&quot;/&quot;no&quot; question to determine a personal or family experience the genetic condition being presented in the scenario (arm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1012</enrollment>
  <condition>Decision Making</condition>
  <arm_group>
    <arm_group_label>rare genetic disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>choice decision frame</intervention_name>
    <description>active choice for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>opt-in decision frame</intervention_name>
    <description>&quot;gain&quot; frame for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>opt-out decision frame</intervention_name>
    <description>&quot;loss&quot; frame for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (context) decision frame</intervention_name>
    <description>consequences of genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (norms) decision frame</intervention_name>
    <description>social norms for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced choice (affect) decision frame</intervention_name>
    <description>commitments for genetic testing</description>
    <arm_group_label>common genetic disease</arm_group_label>
    <arm_group_label>rare genetic disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participants (18-64 yrs) residing in North America (who are members of the
             Amazon Mechanical Turk platform)

        Exclusion Criteria:

          -  age &lt;18yrs or &gt;65yrs or residing outside of North America
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A Dwyer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston College</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

